Google Cloud secures £400 mln U.K. Ministry of Defence sovereign cloud deal
BELLEVUE, Wash. - OSR Holdings (NASDAQ:OSRH) received a notification from Nasdaq on September 5 that the company is not in compliance with the minimum bid price requirement of $1.00 per share, according to a press release issued Tuesday. The stock, currently trading at $0.61, has experienced significant pressure, with InvestingPro data showing a 95% decline year-to-date.
The biopharmaceutical company has until March 4, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). During this period, OSR Holdings’ common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." With a market capitalization of just $12 million and a weak financial health score according to InvestingPro analysis, the company faces significant challenges.
The company stated it is advancing its portfolio of programs in oral immunotherapies and regenerative medicine while building its Digital Asset Treasury strategy. OSR is also conducting due diligence on Woori IO, a developer of non-invasive glucose monitoring technology.
In its statement, OSR Holdings noted concerns about trading activities in its shares that it believes may not align with business fundamentals. The company referenced SEC fails-to-deliver data showing elevated settlement imbalances during periods of trading volatility. InvestingPro data confirms this volatility pattern, with the stock’s beta at 1.51 and current ratio at 0.18, indicating potential liquidity concerns.
"Our focus remains firmly on advancing our scientific programs and creating long-term value for our stakeholders," said Peter Hwang, Chief Executive Officer of OSR Holdings, in the press release.
The company indicated it plans to monitor trading activity and engage with regulators while evaluating options to address what it described as unusual trading dynamics in its securities.
OSR Holdings operates in immuno-oncology, regenerative biologics, and medical device distribution sectors.
In other recent news, OSR Holdings, Inc. reported significant updates regarding its financial and strategic activities. The company has amended its Note Purchase Agreement with White Lion Capital, requiring a shareholder meeting to approve several transactions, including those related to an Equity Line of Credit Agreement. Additionally, OSR Holdings has issued 2,308,382 shares under its structured financing arrangements, with 767,500 shares issued under the Equity Line of Credit with White Lion GBM Innovation Fund. The company is also advancing its acquisition of South Korean medical device company Woori IO Co., Ltd., known for its noninvasive glucose monitoring technology. Under the proposed acquisition, Woori IO would become a wholly owned subsidiary of OSR Holdings’ Korean affiliate, with a share exchange arrangement contingent on OSRH’s stock price reaching $10.00 within three years. Furthermore, OSR Holdings has appointed Dr. Andreas Niethammer as the Chief Medical Officer of its subsidiary, Vaximm AG, bringing over 20 years of experience in cancer immunotherapy and clinical development. These developments reflect OSR Holdings’ strategic moves in both financial structuring and expansion into new medical technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.